TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02006264

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TDF Intravaginal Ring
Description: The TDF IVR intravaginal ring is formulated using flexible outer tubing, comprised of hydrophilic, aliphatic polyether urethane, and an inner core compartment comprised of 86% w/w TDF and 14% w/w sodium chloride (NaCl). The TDF intravaginal ring will be worn continuously for 14 days. It will be inserted into the vagina following cessation of participant's menses at Visit 3 and removed at Visit 7.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Intravaginal Ring
Description: The placebo ring is formulated using flexible outer tubing, comprised of hydrophilic, aliphatic polyether urethane, and an inner core comprised of sodium chloride (NaCl). The Placebo intravaginal ring will be worn continuously for 14 days. It will be inserted into the vagina following cessation of participant's menses at Visit 3 and removed at Visit 7.
Study: NCT00773565

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Optifast
Description: Formula diet for twelve weeks combined with physical activity and behavioral therapy
Study: NCT00613418

Intervention type: DEVICE
Group type: OTHER
Intervention: IDev SUPERA® Interwoven Self Expanding Nitinol Stent Peripheral Vascular System
Description: Interwoven, self-expanding nitinol stent system, including delivery system and stent
Study: NCT00980343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vismodegib
Description: Given orally

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: undergo surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: undergo surgery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: correlative studies
Study: NCT02215408

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CVRS Intervention
Description: A clinical pharmacist working in the University of Iowa CVRS followed each patient for 12 months, working on lifestyle modification and recommending medication changes to the patient's clinical pharmacist in the local clinic.
Study: NCT03956225

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Systane iLux® Dry Eye System
Description: Commercially available medical device intended for use by qualified eye care professionals to apply localized heat and pressure therapy to a patient's eyelids.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LipiFlow® Thermal Pulsation System
Description: Commercially available medical device intended for use by qualified eye care professionals to apply localized heat and pressure therapy to a patient's eyelids.
Study: NCT03659370

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fumigation
Description: use Fumigation to increase the improvement of osteoarthritis of knee

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fumigation
Description: use Fumigation to increase the improvement of osteoarthritis of knee

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Acupuncture
Study: NCT00421603

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adderall-XR and Topiramate
Description: Adderall-XR 60mg/day and Topiramate 300mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01234363

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Elastography, and Supersonic Shear Imaging
Description: Magnetic Resonance Elastography, and Supersonic Shear Imaging
Study: NCT02423291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Brentuximab vedotin, 1.8 mg/kg, administered via outpatient IV infusion on Day 1 of each 21-day cycle.
Study: NCT03306485

Intervention type: OTHER
Intervention: Correlating the number of reflux episodes detected on 1-h post prandial esophageal high resolution manometry combined and those detected on ambulatory 24-h pH-impedance monitoring performed on PPI
Description: Esophageal high resolution impedance manometry (HRIM) consists of introducing a transnasal probe to record esophageal contractility (manometry), bolus transit (impedance) but also the occurrence of reflux episodes. Ambulatory 24-h pH-impedance monitoring consists of recording the occurrence of reflux episodes by introducing a transnasal catheter into the esophagus. After inserting the transnasal HRIM probe and the pH-impedance catheter, both HRIM and 24-h pH-impedance recordings are started. The patient is instructed to eat a meal that induces reflux symptoms (the patient brings his own meal). One hour the end of the meal, the HRIM probe is removed. The patient is discharged at home and the 24-h pH-impedance monitoring is continued. The patient is coming back 24-h after catheter insertion to stop the pH-impedance recording and remove the catheter.
Study: NCT02763293

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy
Description: Non-manipulative treatment osteopathic techniques combined direct and indirect soft appropriate in patients with Crohn's disease
Study: NCT03172858

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intracervical balloon catheter
Description: cervical ripening balloon

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: medication used to induce contractions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: medication used to induce contractions
Study: NCT00418964

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single bundle hamstring
Description: Single bundle hamstring

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Double bundle hamstring
Description: Double bundle hamstring

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone patellar tendon bone
Description: Bone patellar tendon bone
Study: NCT01062568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adrenocorticotropin
Description: Subjects will have blood drawn at 1900 hr for baseline hormone measurements. At 2200 hr each subject will take a single oral dose of dexamethasone at 2200 hr. At 0700 hr the following day, subjects will have a blood sample drawn for hormone measurements. After this blood sample, adrenocorticotropin (ACTH) will be administered as an iv bolus. At 30 and 60 minutes after Cosyntropin, blood samples will be obtained for repeat hormone measurements.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adrenocorticotropin
Description: Subjects will have blood drawn at 1900 hr for baseline hormone measurements. At 2200 hr each subject will take a single oral dose of dexamethasone at 2200 hr. At 0700 hr the following day, subjects will have a blood sample drawn for hormone measurements. After this blood sample, adrenocorticotropin (ACTH) will be administered as an iv bolus. At 30 and 60 minutes after Cosyntropin, blood samples will be obtained for repeat hormone measurements.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Subjects will have blood drawn at 1900 hr for baseline hormone measurements. At 2200 hr each subject will take a single oral dose of dexamethasone at 2200 hr. At 0700 hr the following day, subjects will have a blood sample drawn for hormone measurements. After this blood sample, 0.25 mg adrenocorticotropin (ACTH) will be administered as an iv bolus. At 30 and 60 minutes after Cosyntropin, blood samples will be obtained for repeat hormone measurements.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Subjects will have blood drawn at 1900 hr for baseline hormone measurements. At 2200 hr each subject will take a single oral dose of dexamethasone at 2200 hr. At 0700 hr the following day, subjects will have a blood sample drawn for hormone measurements. After this blood sample, 0.25 mg adrenocorticotropin (ACTH) will be administered as an iv bolus. At 30 and 60 minutes after Cosyntropin, blood samples will be obtained for repeat hormone measurements.
Study: NCT01909167

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online Cognitive Behavioral Therapy (CBT)
Description: CBT treatment: Patients randomized to the online treatment will have, in total, 10 real time individual sessions of 40min each, starting at the 20-23rd gestational week and lasting until 6 weeks postpartum. The therapy will be delivered every two weeks, with a break from the 36th gestational week until the 4th week postpartum.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Patients randomized to the treatment as usual arm will be advised by their GP,perinatal psychiatric team or mental health midwife concerning treatment.
Study: NCT03957798

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RecoveryWarrior 2.0
Description: RecoveryWarrior 2.0 was developed for use with Microsoft Kinect running on a Windows personal computer. All games made use of whole-body motion detection and the same voice-recognition feature. Body motions included a variety of arm, leg, and whole-body movements to physically enact the motions of destroying or evading images of drugs and drug paraphernalia. Voice features consisted of recognition of the refusal phrase I'm Clean Players could say or shout I'm Clean in order to gain additional strength for their game play avatar. All game art was created in a hyperrealistic, idealized, heroic style.
Study: NCT04665440

Intervention type: OTHER
Group type: OTHER
Intervention: Voice alone
Description: mother's voice without tactile stimuli

Intervention type: OTHER
Group type: OTHER
Intervention: Voice alone
Description: mother's voice without tactile stimuli

Intervention type: OTHER
Group type: OTHER
Intervention: Voice + tactile stimuli
Description: mother's voice with tactile stimuli

Intervention type: OTHER
Group type: OTHER
Intervention: Voice + tactile stimuli
Description: mother's voice with tactile stimuli
Study: NCT01414738

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Hippocampal-Avoiding Whole Brain Irradiation with Simultaneous Integrated Boost
Study: NCT04204993

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lumee Oxygen Platform
Description: Two sensors will be inserted (one in the skin fo the upper arm and one on the side of the chest). A wireless patch reader is placed on top of the skin over the area where the sensor has been placed to measure local oxygen content.
Study: NCT01831700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisinopril and Hydrochlorothiazide Tablets (20+25) mg
Description: Lisinopril and Hydrochlorothiazide (20+25) mg Tablets once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisinopril and Hydrochlorothiazide Tablets (20+25) mg
Description: Lisinopril and Hydrochlorothiazide (20+25) mg Tablets once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets
Description: Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets once a day
Study: NCT04032158

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Evobrutinib matched Placebo
Description: Participants received placebo matched to evobrutinib twice a day.
Study: NCT01831700

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets
Description: Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets once a day
Study: NCT02214160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UX007
Description: Administered orally (PO) with food or by gastrostomy tube, at the target dose range of 25-35% of total calories.
Study: NCT00331071

Intervention type: DRUG
Intervention: Monophasic or triphasic Oral contraceptive tablet
Description: fourth week is patch free

Intervention type: DRUG
Intervention: Ortho Evra transdermal patch containing 6 mg NGMN/0.75 mg EE
Description: worn for 1 week and replaced for 3 consecutive weeks
Study: NCT01300052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AN2728 ointment, 2%
Description: AN2728 ointment, 2%, applied twice daily for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ointment Vehicle
Description: Ointment Vehicle, applied twice daily for 12 weeks
Study: NCT03145402

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intracoronary injection of stem cell
Description: Autologous bone marrow-derived mononuclear cells are obtained from 100-150ml of bone marrow aspirated under local anaesthesia from the iliac crest. Intracoronary infusion of the cells is performed in patients with Heart failure via conventional percutaneous intracoronary intervention techniques.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injection of Placebo in patients with Heart failure via coronary arteries
Study: NCT03433755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: evolocumab
Description: Evolocumab will be administered per pre-filled auto-injector pen (AI/Pen). Participants will receive evolocumab (AMG 145) every 2 weeks or monthly subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: evolocumab
Description: Evolocumab will be administered per pre-filled auto-injector pen (AI/Pen). Participants will receive evolocumab (AMG 145) every 2 weeks or monthly subcutaneously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo will be administered per pre-filled auto-injector pen (AI/Pen). Participants will receive placebo every 2 weeks or monthly subcutaneously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo will be administered per pre-filled auto-injector pen (AI/Pen). Participants will receive placebo every 2 weeks or monthly subcutaneously.
Study: NCT04293549

Intervention type: DRUG
Intervention: Cenegermin, recombinant human Nerve Growth Factor (rhNGF) eyedrops
Description: rhNGF 20µg/ml (Cenegermin) eyedrops, 1 drop every 2 hours (6 times a day) for 8 weeks.~Patients underwent clinical examination with corneal fluorescein staining, Schirmer I tear test, assessment of corneal sensitivity with Cochet-Bonnet aesthesiometer and morphological examination of the nerves by In Vivo Confocal Microscopy (IVCM) at baseline and after 4 and 8 weeks of treatment
Study: NCT04574128

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No retransfusion of cardiotomy blood
Description: No retransfusion of cardiotomy blood via heart- and lung mashine
Study: NCT03329079

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Technology Plus
Description: The intervention group MT+ will receive the premium-version mobile phone app with social comparison group, behavior change text messaging, and daily self-weighing via Wi-Fi scale.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mobile Technology
Description: The comparison group MT will receive the basic-version mobile phone app only to self monitor eating, activity, and weight.
Study: NCT00207948

Intervention type: DRUG
Intervention: Dose adjustment of Kaletra
Description: Adjust the dose by up to +50% of reccomended dosa off the drug to meet target therapeutic concentrations
Study: NCT01923194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Highly Purified Urofollitropin
Description: for Injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Human Follitropin Alfa
Description: for Injection
Study: NCT02632734

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CoreBone Cone device
Description: coral derived devices in the form of Cones are placed in extraction sites for preservation of bone during 6month and more.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CoreBone 500 device
Description: coral derived devices in the form of particulate (CoreBone 500) are placed in extraction sites for preservation of bone. Follow up during 6month and more.
Study: NCT04013945

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Superba Boost (Active)
Description: To assess changes in Trans-epidermal water loss (TEWL), measured at baseline and after 12 weeks of daily consumption with Superba Boost.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vegetable oil (Placebo)
Description: To assess changes in Trans-epidermal water loss (TEWL), measured at baseline and after 12 weeks of daily consumption with Placebo.
Study: NCT05120102

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diode laser
Description: K2 diode laser of 980nm wavelength
Study: NCT01385306

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AlphaCore System
Description: Non-invasive neurostimulation of the vagus nerve
Study: NCT01846273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Intravitreal injection of 0.5 mg ranibizumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Intravitreal injection of 0.5 mg ranibizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verteporfin PDT
Description: Infusion of 30 ml verteporfin in 5% dextrose solution followed by 83 sec of laser light (50J/cm2; 600mW/cm2; 689 nm)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sham PDT
Description: Infusion of 30 ml 5% dextrose solution followed by 83 sec of laser light (50J/cm2; 600mW/cm2; 689 nm)
Study: NCT00970008

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Massage 30 min 2x/wk x4 wks then 1x/wk x4 wks
Description: Swedish massage session of 30 minutes duration, twice weekly for four weeks followed by once weekly for four weeks over a eight (8) week period. Total intervention = 12 sessions for 360 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Massage 60 min 2x/wk for 4 wks then 1x/wk for 4 wks
Description: Swedish massage session of 60 minutes duration, twice weekly for four weeks followed by once weekly for four weeks over a eight (8) week period. Total intervention = 12 sessions for 720 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Massage 30 min sessions 1x/wk for 8 wks
Description: Swedish massage session of 30 minutes duration, once weekly for eight weeks over a eight (8) week period. Total intervention = 8 sessions for 240 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Massage 60 min session 1x/wk for 8 wks
Description: Swedish massage session of 60 minutes duration, once weekly for eight weeks over a eight (8) week period. Total intervention = 8 sessions for 480 minutes
Study: NCT01569776

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Amino Acid formula
Description: Amino Acid baby formula

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Commercially available Amino Acid Formula
Description: Hypoallergenic Baby formula
Study: NCT00366041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dermal substrate cellularised LG002 (10x10cm)
Description: application depending on burn injury surface

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dermal substrate uncellularised LG002 (10x10 cm)
Description: depending on burn injury surface
Study: NCT05649735

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Logusgyn ovules
Description: LOGUSGYN ovules is a CE certified Class I medical device, according to MD Directive 93/42 / EEC as amended by Directive 2007/47 / EC, manufactured by ERBOZETA S.p.a. designed for its intended use. It consists of a vaginal ova dressing for topical use containing tindalised cultures, Guar fibre, Lactic acid and Calendula.~It is supplied in a container with 10 vaginal ova. For this study, LOGUSGYN/CANDIDEP ova/wash will be packaged according to good manufacturing practice and local regulatory requirements and will be labelled in accordance with local regulatory requirements and according to GMP Annex 13.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Logusgyn ovules
Description: LOGUSGYN ovules is a CE certified Class I medical device, according to MD Directive 93/42 / EEC as amended by Directive 2007/47 / EC, manufactured by ERBOZETA S.p.a. designed for its intended use. It consists of a vaginal ova dressing for topical use containing tindalised cultures, Guar fibre, Lactic acid and Calendula.~It is supplied in a container with 10 vaginal ova. For this study, LOGUSGYN/CANDIDEP ova/wash will be packaged according to good manufacturing practice and local regulatory requirements and will be labelled in accordance with local regulatory requirements and according to GMP Annex 13.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Logusgyn Lavander
Description: LOGUSGYN lavage is a CE certified class I medical device, according to MD Directive 93/42 / EEC as amended by Directive 2007/47 / EC, manufactured by ERBOZETA S.p.a. designed for its intended use. It consists of a gynaecological lavage dressing containing Chlorhexidine 0.2% and tindalised ferments, lactic acid, bisabolol.~It is supplied in a container with 5 vaginal douches.~For this study, LOGUSGYN/CANDIDEP ova/wash will be packaged according to good manufacturing practice and local regulatory requirements and will be labelled in accordance with local regulatory requirements and according to GMP Annex 13.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Logusgyn Lavander
Description: LOGUSGYN lavage is a CE certified class I medical device, according to MD Directive 93/42 / EEC as amended by Directive 2007/47 / EC, manufactured by ERBOZETA S.p.a. designed for its intended use. It consists of a gynaecological lavage dressing containing Chlorhexidine 0.2% and tindalised ferments, lactic acid, bisabolol.~It is supplied in a container with 5 vaginal douches.~For this study, LOGUSGYN/CANDIDEP ova/wash will be packaged according to good manufacturing practice and local regulatory requirements and will be labelled in accordance with local regulatory requirements and according to GMP Annex 13.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile saline solution
Study: NCT02249676

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous mesenchymal stem cells
Description: Autologous mesenchymal stem cells

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Autologous mesenchymal stem cells
Description: Autologous mesenchymal stem cells